With this paper, we deliberately challenge the prevailing neurocentric theory of the etiology of spinal bulbar muscular atrophy (SBMA). We offer data supporting an alternative view that androgen receptor (AR) acts in skeletal muscles to cause the symptoms of SBMA. While SBMA has been linked to a CAG repeat expansion in the AR gene and mutant AR is presumed to act in motoneurons to cause SBMA, we find that over-expression of wild type AR solely in skeletal muscle fibers results in the same androgen-dependent disease phenotype as when mutant AR is broadly expressed. Like other recent SBMA mouse models, transgenic (tg) females in our model exhibit a motor phenotype only when exposed to androgens, and this motor dysfunction is independent of motoneuronal or muscle fiber cell death. Muscles from symptomatic females also show denervation-like changes in gene expression comparable to a knock-in model of SBMA. Furthermore, once androgen treatment ends, tg females rapidly recover motor function and muscle gene expression, demonstrating the strict androgen-dependence of the disease phenotype in our model. Our results argue that SBMA may be caused by AR acting in muscle.
Introduction
Spinal bulbar muscular atrophy (SBMA) is an adult onset, slowly progressive lower motoneuron disease characterized by proximal limb and bulbar muscle weakness and atrophy affecting primarily men. This disease is linked to an expansion of a CAG repeat in the androgen receptor (AR) gene, coding for an expanded polyglutamine (polyQ) repeat in the AR protein (La Spada et al., 1991) . Most clinical evaluations conclude that muscle pathology represents neurogenic atrophy that is secondary to motoneuronal death (Zoghbi and Orr, 2000) .
Data from our 'myogenic' mouse model challenges this neurocentric view of SBMA. We find that mice expressing an AR transgene exclusively in skeletal muscle fibers show the same male-biased, androgen-dependent loss of motor function (Monks et al., 2007) as described for other SBMA mouse models that broadly express a polyQ expanded AR (Katsuno et al., 2002; McManamny et al., 2002; Sopher et al., 2004; Yu et al., 2006) . Moreover, in our model, a wild type AR with 22 glutamines mediates the androgen-induced toxicity.
Given the current view of SBMA, we were quite surprised that our transgenic (tg) mice exhibit a SBMA-like phenotype, since they neither express an expanded polyQ allele nor an AR transgene in motoneurons. Nonetheless, our tg model has the following characteristics: 1) only tg males show a loss of motor function, but 2) androgen exposure induces the disease in tg females, 3) disease symptoms in late-stage tg males are accompanied by deficits in the number of muscle fibers and motor axons, and 4) castration rescues motor function in severely diseased tg males, casting doubt on the relationship between cell loss and motor dysfunction (Monks et al., 2007) . Finally, muscles of symptomatic tg males show expected changes in the expression of genes implicated in SBMA (Sopher et al., 2004; Yu et al., 2006) .
That high expression of a wild type allele can induce comparable pathology as a neurodegenerative mutant allele is not without precedence, and includes synuclein implicated in Parkinson's (Singleton et al., 2003) , ataxin in spinocerebellar ataxia (Fernandez-Funez et al., 2000; Tsuda et al., 2005) , tau in Alzheimer's (Wittmann et al., 2001 ) and SOD1 in ALS (Jaarsma et al., 2000) . Even AR has been reported to induce a ligand-dependent toxicity in cell models of SBMA that is independent of polyQ length (Grierson et al., 2001; Walcott and Merry, 2002) , challenging our understanding of the factors regulating AR protein toxicity. Because over-expression of wt AR in muscle fibers results in a strict androgen-dependent loss of motor function mimicking a well described SBMA phenotype in mice, we hypothesize that androgen normally acts in muscles to trigger SBMA. 
